Entre 20% e 30% dos pacientes com psoríase vulgar têm formas exuberantes que requerem terapia sistêmica. A imunobiologia representa um ramo promissor da farmacologia moderna e configura um dos grandes avanços da medicina atual. O secuquinumabe é um anticorpo monoclonal de imunoglobulina humana totalmente recombinante, recentemente introduzido no mercado, que atua neutralizando seletivamente a interleucina17-A e promove excelentes resultados no tratamento de casos moderados a graves de psoríase. Apresentamos uma paciente de 66 anos internada por psoríase artropática eritrodérmica e tratada com secuquinumabe sob regime de monoterapia. Houve melhora importante das lesões cutâneas após 6 semanas e resolução completa do quadro, inclusive da artrite, após 10 semanas de tratamento. (AU)
Between 20% and 30% of patients with psoriasis have exuberante forms that require systemic therapy. Immunobiology represents a promising branch of modern pharmacology and is one of the great advances of current medicine. Secukinumab is a recently released recombinant humanimmunoglobulinmonoclonal antibody that selectively neutralizes interleukin17A and promotes excelente results in the treatment of moderate to severe cases of psoriasis. We present a 66 year old patient hospitalized for erythrodermic arthropathic psoriasis and treated by a monotherapy regimen with secukinumab. There was significant mprovement of skin lesions after 6 weeks and complete resolution of the condition, including the arthritis, after 10 weeks of treatment. (AU)